CEO’s Letter Expanding our strategy to deliver value Noxopharm Limited 6 It is both a pleasure and an honour to write my first Annual Report letter to you as CEO, and let me begin by thanking you all for your ongoing support of Noxopharm. Since assuming this role in early 2022, the senior management team and I have been very appreciative of the encouragement we’ve received from shareholders, and can assure you we are deeply committed to the success of this company. For those of you who do not know me, my background is working in leadership roles around the world in many highprofile pharma companies to help them deliver new drugs to patients. This has given me not only direct experience of the journey from molecule to marketplace, but also a strong network of international industry relationships, all of which will prove very useful as we continue to grow Noxopharm. Personally, I am driven by the desire to tackle some of the most debilitating illnesses of our time, and have worked on many of these in my career, from cancer to cardiovascular diseases. It was this passion that drove me to accept the opportunity to lead Noxopharm. My aim is to ensure the company maximises its potential as we mature our operations and sharpen our strategic ambitions. Of course, I am not alone in this, and work closely with a highly skilled management team who deliver depth and strength across the company, from R&D knowledge in oncology and inflammation to significant financial and operational experience. Taken together, we have more than 100 years of scientific and pharmaceutical industry experience between us. We also have some very talented younger scientists on our team, who every day are exploring new ways to build our future through experimentation, creativity and innovation – backed by rigorous scientific analysis and a commitment to data-driven decision-making. It is challenging to develop lifeDear fellow Shareholders,
RkJQdWJsaXNoZXIy MjE2NDg3